Matthew L. Sherman - 17 Jan 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role
EVP & Chief Medical Officer
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
17 Jan 2023
Net transactions value
-$51,043
Form type
4
Filing time
19 Jan 2023, 15:05:51 UTC
Previous filing
05 Oct 2022
Next filing
17 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Sale $51,043 -2,403 -3.2% $21.24 72,628 17 Jan 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was to cover tax liabilities in the vesting of restricted stock.
F2 Includes 734 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 14, 2022.